ScoreWhy is Harbin Gloria Pharmaceuticals Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 5.00%
- The company has been able to generate a Return on Capital Employed (avg) of 5.00% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -9.06% and Operating profit at 41.18% over the last 5 years
3
Positive results in Mar 25
- OPERATING CASH FLOW(Y) Highest at CNY 370.6 MM
- NET PROFIT(HY) Higher at CNY 113.65 MM
- ROCE(HY) Highest at 12.86%
4
With ROE of 11.86%, it has a fair valuation with a 3.24 Price to Book Value
- Over the past year, while the stock has generated a return of 26.67%, its profits have risen by 1.3% ; the PEG ratio of the company is 3.9
5
Market Beating Performance
- The stock has generated a return of 26.67% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.18%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Harbin Gloria Pharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Harbin Gloria Pharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Harbin Gloria Pharmaceuticals Co., Ltd.
25.78%
1.96
43.32%
China Shanghai Composite
15.19%
1.01
15.10%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-9.06%
EBIT Growth (5y)
41.18%
EBIT to Interest (avg)
9.96
Debt to EBITDA (avg)
0.31
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.11
Tax Ratio
12.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.00%
ROE (avg)
4.75%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
3.24
EV to EBIT
27.29
EV to EBITDA
19.45
EV to Capital Employed
3.99
EV to Sales
2.68
PEG Ratio
3.87
Dividend Yield
NA
ROCE (Latest)
14.63%
ROE (Latest)
11.86%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 370.6 MM
NET PROFIT(HY)
Higher at CNY 113.65 MM
ROCE(HY)
Highest at 12.86%
DEBT-EQUITY RATIO
(HY)
Lowest at -27.35 %
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
DEBTORS TURNOVER RATIO(HY)
Highest at 14.74%
-6What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 8.51% (YoY
CASH AND EQV(HY)
Lowest at CNY 1,113.96 MM
NET SALES(Q)
Lowest at CNY 542.57 MM
OPERATING PROFIT(Q)
Lowest at CNY 57.75 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 10.64 %
Here's what is working for Harbin Gloria Pharmaceuticals Co., Ltd.
Net Profit
At CNY 113.65 MM has Grown at 376.18%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 370.6 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Profit
Higher at CNY 113.65 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Debt-Equity Ratio
Lowest at -27.35 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 14.74%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Harbin Gloria Pharmaceuticals Co., Ltd.
Net Sales
Lowest at CNY 542.57 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Net Sales
At CNY 542.57 MM has Fallen at -9.83%
over average net sales of the previous four periods of CNY 601.73 MMMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Operating Profit
Lowest at CNY 57.75 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 10.64 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Cash and Eqv
Lowest at CNY 1,113.96 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 8.51% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
